The Role of Omega-3 Fatty Acids in Acute Pancreatitis: A Meta-Analysis of Randomized Controlled Trials

Nutrients

Qiu Cheng Lei²  Xin Ying Wang²  Xian Feng Xia³  Hua Zhen Zheng¹  Jing Cheng Bi⁴  Feng Tian⁴ 

[1] Key Laboratory for Medical Molecular Diagnostics of Guangdong Province, Guangdong Medical College, Dongguan 523808, China; E-Mail:;Graduate School, Southern Medical University, Guangzhou 510515, China; E-Mail:;Department of Surgery, Prince of Wales Hospital, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong 999077, China; E-Mail:;Research Institute of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China; E-Mails:

关键词: acute pancreatitis;    omega-3 fatty acids;    nutrition support;    parenteral nutrition;    enteral nutrition;    meta-analysis;   

DOI  :  10.3390/nu7042261

来源: mdpi

【 摘 要 】

To determine whether treatment with omega-3 fatty acids (ω-3 FA) provides benefits to patients with acute pancreatitis (AP). The Cochrane Library, PubMed, Embase, Web of Science, and Chinese Biomedical Literature Database were searched. Data analysis was performed using Revman 5.2 software. A total of eight randomized controlled trials (RCTs) were included. Overall, ω-3 FA treatment resulted in a significantly reduced risk of mortality (RR 0.35; 95% CI 0.16 to 0.75, p < 0.05), infectious complications (RR 0.54; 95% CI 0.34 to 0.85, p < 0.05) and length of hospital stay (MD –6.50; 95% CI −9.54 to −3.46, p < 0.05), but not length of ICU stay (MD −1.98; 95% CI −6.92 to 2.96, p > 0.05). In subgroup analysis, only patients who received ω-3 FA parenterally had some statistically significant benefits in terms of mortality (risk ratio (RR) 0.37; 95% confidence interval (CI) 0.16 to 0.86, p < 0.05), infectious complications (RR 0.5; 95% CI 0.28 to 0.9, p < 0.05) and length of hospital stay (mean difference (MD) −8.13; 95% CI −10.39 to −5.87, p < 0.001). The administration of ω-3 FA may be beneficial for decreasing mortality, infectious complications, and length of hospital stay in AP, especially when used parenterally. Large and rigorously designed RCTs are required to elucidate the efficacy of parenteral or enteral ω-3 FA treatment in AP.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.